$250 Million

Vera Therapeutics, Inc.

Follow-on Offering

Bookrunner, January 2024

Vera Therapeutics, Inc.

Vera Therapeutics, Inc (“Vera” or the “Company”) is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera’s lead product candidate, atacicept, is a self-administered fusion protein that blocks both B-cell activating factor, or BAFF, also known as B-lymphocyte stimulator, or BLyS, and a proliferation-inducing ligand, or APRIL, with best-in-class potential for the treatment of immunoglobulin A nephropathy, or IgAN.